New combination treatment offers significant benefits for people with recurring grade 3 astrocytoma

0
1

Huntsman Cancer Institute at the University of Utah (the U) participated in a clinical trial that found that a new combination treatment plan helped people with recurring grade 3 astrocytoma, an aggressive form of brain cancer, live longer.

To continue reading click here

This site uses Akismet to reduce spam. Learn how your comment data is processed.